Objective-Ischemic stroke, which is mainly caused by thromboembolic occlusion of brain arteries, is the second leading cause of death and disability worldwide with limited treatment options. The platelet collagen receptor glycoprotein VI (GPVI) is a key player in arterial thrombosis and a critical determinant of stroke outcome, making its signaling pathway an attractive target for pharmacological intervention. The spleen tyrosine kinase (Syk) is an essential signaling mediator downstream of not only GPVI but also other platelet and immune cell receptors. We sought to assess whether Syk might be an effective antithrombotic target. Approach and Results-We demonstrate that mice lacking Syk in platelets specifically are protected from arterial thrombus formation and ischemic stroke but display unaltered hemostasis. Furthermore, we show that mice treated with the novel, selective, and orally bioavailable Syk inhibitor BI1002494 were protected in a model of arterial thrombosis and had smaller infarct sizes and a significantly better neurological outcome 24 hours after transient middle cerebral artery occlusion, also when BI1002494 was administered therapeutically, that is, after ischemia. Conclusions-These results provide direct evidence that pharmacological Syk inhibition might provide a safe therapeutic strategy to prevent arterial thrombosis and to limit infarct progression in acute stroke. (Arterioscler Thromb Vasc Biol.
P latelet aggregation is not only essential for hemostasis but also a major pathomechanism underlying myocardial infarction and ischemic stroke. Therefore, platelet inhibition is commonly used in secondary stroke prevention. 1 In acute stroke, however, revascularization by recombinant tissue-type plasminogen activator or mechanical thrombectomy are the only therapeutic means 1,2 with limited efficacy. 3 Addition of conventional antiplatelet agents, such as acetylsalicylic acid, led to bleeding complications. 4 To improve functional outcome in acute stroke, novel antithrombotic strategies preserving physiological hemostasis are eagerly awaited.
See accompanying editorial on page 1054
The spleen tyrosine kinase (Syk) is a 72-kDa multiple-domain cytoplasmic tyrosine kinase, which is highly expressed in hematopoietic cells. Syk acts downstream of immunoreceptor tyrosine-based activation motif (ITAM)coupled receptors, such as the B-cell receptor or Fcγ receptors (FcγRs) in macrophages. In platelets, Syk is essential for signaling downstream of the (hem)ITAM receptors glycoprotein VI (GPVI), C-type lectin-like receptor 2 (CLEC-2), and the FcγRIIA, the latter being present on human but not on murine platelets. 5 FcγRIIA signals through an ITAM in its cytoplasmic tail and is critically involved in immune-mediated thrombocytopenia and thrombosis, but it also enhances platelet integrin outside-in signaling via Syk. 5 GPVI signals via the noncovalently associated ITAM-bearing FcR γ-chain. On ligand-induced receptor ligation of GPVI, the tyrosine residues in the ITAM become phosphorylated by Src family kinases, inducing the recruitment and activation of the tandem Src homology 2 domain-containing kinase Syk. CLEC-2 only contains 1 copy of the YxxL motif (hemITAM) and is expressed as a homodimer on the platelet surface. In contrast to classical ITAM signaling, recent studies suggest that Syk itself phosphorylates the hemITAM within CLEC-2, 6 whereas the Src family kinases together with Syk are involved in the regulation of the downstream signaling cascade via the linker of activated T cells signalosome, ultimately leading to the activation of phospholipase Cγ2. Because of the central role of Syk in immunologic processes, several Syk inhibitors have been developed and clinically used, such as the prodrug fostamatinib (R788) 7, 8 and its active metabolite R406. 9 However, these inhibitors have a rather limited specificity and adverse effects. 10 Recently, entospletinib (GS-9973) was developed and described as a more selective and orally efficacious Syk inhibitor 11 ; however, Thoma et al 12 showed only modest activity of GS-9973. Phase II trials are now underway to assess its effectiveness in treating leukemia. 13 Syk inhibitors have been used in the treatment of allergy, 14 B-cell malignancies, 7 heparin-induced thrombocytopenia, 15 and autoimmune diseases, such as rheumatoid arthritis 8 and immune thrombocytopenic purpura. 16 Although Syk is critical for platelet signaling, a possible significance of Syk-mediated signaling in the pathogenesis of ischemic stroke has not been established to date. Here, we show that a platelet-specific Syk deficiency or treatment with the novel selective and orally bioavailable Syk inhibitor, BI1002494, profoundly protects mice from arterial thrombosis and cerebral infarct progression while not increasing the risk of intracranial hemorrhage.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Syk fl/fl, Pf4-cre+/− mice displayed normal basal blood parameters and surface expression of major platelet glycoproteins (Table and not shown). Flow cytometric analyses revealed unaltered platelet integrin activation (JON-A/PE binding) and degranulation (P-selectin exposure) in response to G-protein-coupled receptor agonists but abolished responses to GPVI and CLEC-2 agonists collagen-related peptide and rhodocytin, respectively ( Figure 1A and 1B, not shown) confirming previous results. 6, 17 Lack of functional Syk also resulted in abolished platelet aggregation in response to GPVI or CLEC-2 agonists ( Figure 1C and not shown). However, outside-in signaling of integrin αIIbβ3 as assessed in a platelet-spreading assay was unaffected in Syk-deficient platelets ( Figure 2) .
A combined GPVI and CLEC-2 deficiency dramatically affects hemostasis, 18 whereas no such defect was observed in a small group of bone marrow chimeric Syk-deficient mice. 19 In line with the latter report, Syk fl/fl, Pf4-cre+/− mice displayed moderately prolonged tail bleeding times ( Figure 3A ). However, occlusive thrombus formation on mechanical injury of the abdominal aorta was abrogated in Syk fl/fl,Pf4-cre+/− mice ( Figure 3B ), confirming an important role for Syk in arterial thrombosis. To assess the role of platelet Syk in brain infarction after focal cerebral ischemia, mice were subjected to 60-minute transient middle cerebral artery occlusion (tMCAO), and infarct volume and neurological deficits were assessed after 24 hours. Strikingly, the infarct volumes in Syk fl/fl,Pf4-cre+/− mice were significantly reduced compared with wild-type mice ( Figure 3C and 3D). Motor function, as assessed using the grip test, displayed a tendency toward improved outcome ( Figure 3E ), and the Bederson score assessing global neurological function was significantly improved ( Figure 3F ). Remarkably, no intracerebral hemorrhages were observed in these animals by systematic microscopical inspection (not shown). Thus, Syk deficiency in platelets provides protection against occlusive arterial thrombus formation and cerebral infarct progression, indicating that Syk might be an attractive antithrombotic/antithromboinflammatory target.
To test this directly, we used commercially available inhibitors, but the efficacy in vivo was limited. Therefore, we capitalized on the novel and highly selective oral ATPcompetitive Syk inhibitor, BI1002494. 20 In vitro, 150 nmol/L BI1002494 abrogated collagen-related peptide responses of wild-type platelets, whereas a concentration of 500 nmol/L was required to completely abolish convulxin and rhodocytin responses ( Figure 4A and 4B). In contrast, no effects on G-protein-coupled receptor signaling were observed with any of the tested inhibitor concentrations ( Figure 4A and 4B). BI1002494-treated mouse platelets were able to spread normally on a fibrinogen-coated surface, but interestingly outside-in signaling of integrin αIIbβ3 in human platelets was impaired on inhibitor treatment ( Figure 5 and not shown). Oral administration of a single dose of the inhibitor (100 mg/ kg) 1 hour before blood drawing led to inhibition of platelet aggregation on stimulation of (hem)ITAM receptors (data not shown). However, these results were variable, and to maintain a constant plasma exposure for a longer time period, mice were treated twice, 15 hours and 1 hour before the experiments. To perform in vivo experiments, plasma exposure of the inhibitor was required for a longer time period. Oral administration of BI1002494 (100 mg/kg BID) in mice resulted in plasma concentrations >980 nmol/L during a 24-hour time period (D. Lamb et al, unpublished data, 2015) . Subsequent ex vivo analysis of platelet-rich plasma showed abolished GPVItriggered platelet aggregation, whereas rhodocytin responses were reduced, but not abolished ( Figure 4C ). Interestingly, tail Figure 6A ). Bl1002494-treated mice were subjected to mechanical injury of the aorta and found to be completely protected from vessel occlusion ( Figure 6B ). Next, wild-type mice were pretreated with Bl1002494 and then subjected to 60-minute tMCAO to determine the effect of the Syk inhibitor on ischemia-reperfusion injury. Similar to Syk fl/fl, Pf4-cre+/− mice, these animals displayed markedly reduced infarct sizes and improved motor function 24 hours after tMCAO but no evidence of major intracerebral bleeding ( Figure 6C , not shown). To assess if the Syk inhibitor could be used therapeutically in an experimental setting, that is, when given after ischemia, mice were treated with the inhibitor directly after tMCAO (directly on removal of the filament), mimicking patients undergoing thrombectomy and subsequent treatment. Strikingly, also under these conditions, inhibitor-treated mice had reduced infarct sizes and a better motor function as compared with the vehicle-treated controls ( Figure 6C-6F ). Together, these results indicate that Syk inhibition might be effective in preventing cerebral reperfusion injury in patients after successful thrombectomy. 
Discussion
The unaltered bleeding times in Bl1002494-treated mice are in line with observations made with other Syk inhibitors, such as fostamatinib 21 or PRT060318, 15, 22 and strongly suggest that Syk inhibition might be a safe antithrombotic regimen. However, as with all preclinical studies, differences between animal studies and the human situation need to be considered. One notable difference is the expression of FcγRIIA, which is present on human but not on mouse platelets. This difference in expression is the most likely explanation for the observed differences between human and mouse platelet spreading on inhibitor treatment because FcγRIIA supports platelet spreading in human platelets. Besides its effect on FcγRIIA, Bl1002494 dose dependently abolished (hem)ITAM signaling in platelets, wherein collagen-related peptide-induced platelet activation seemed to be more sensitive toward inhibition than convulxin or rhodocytin-induced platelet activation. Different clustering capacities or variation in receptor-binding sites of the different agonists might contribute to these different sensitivities. 23 Similar agonist and signaling pathway-dependent differences in Bl1002494 efficacy were observed in various immune cells. 20 Furthermore, GPVI and CLEC-2 signaling differ in the sequential order of Src family kinases and Syk, 6 which could explain the different potencies of BI1002494 for inhibiting GPVI and CLEC-2 signaling and thereby the unaltered tail bleeding times in inhibitor-treated mice compared with the slightly prolonged bleeding times in Syk-deficient mice. However, given previous reports that the concomitant lack of GPVI and CLEC-2 severely compromises hemostasis, 18 this could also point toward signaling-independent functions of the 2 (hem)ITAM receptors in hemostasis. Although our studies indicate that short-term inhibition of Syk is well tolerated, a longer treatment should be carefully considered because Syk deficiency could result in a blood-lymphatic mixing phenotype [24] [25] [26] or defective integrity of high endothelial venules, 27 indicating that chronic Syk inhibition might have a similar effect in mice and possibly humans. However, blood-lymphatic mixing or blood-filled lymph nodes were not observed in the Syk-deficient mice used for our studies. It was of our interest to determine the role of Syk in ischemia-reperfusion injury, a phenomenon that often occurs on recanalization of occluded cerebral arteries in the setting of acute stroke. The tMCAO model is a well-established model to study this process and clinically reflects thrombectomy. The therapeutic setting, in which mice were treated with BI1002494 directly on removal of the filament, would reflect a clinical situation where a patient undergoes successful thrombectomy with additional treatment with an antiplatelet agent. In the Syk-deficient mice, the neurological outcome was significantly improved, whereas only a tendency toward a better motor function was observed. In contrast, the inhibitor-treated mice have a significantly improved motor function. However, a clear reduction of infarct sizes was observed for both Syk-deficient and inhibitor-treated mice, and this was reflected by the improved outcomes in the neurological and motor function tests. In addition, our data were obtained using mouse models, and when translating the results to a clinical situation, other risk factors, besides dysregulated platelet function, such as atherosclerosis, diabetes mellitus, hypertension, and obesity have to be taken into account.
In conclusion, we could demonstrate that pharmacological inhibition of Syk results in efficient and safe protection from arterial thrombosis and acute ischemic stroke without affecting hemostasis. 
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